Navigation Links
A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy

KIEL, Germany, March 5 /PRNewswire/ -- In mid-March the German Bundestag (Lower House) is due to vote on an amendment to the German Stem Cell Act. The opposing poles in the debate on embryonic stem cell research could not be further apart: its proponents are calling for the complete liberalisation of stem cell research, while its critics are in favour of a general ban on the use of human stem cells, which are produced from embryos. While the Bundestag debates on a new regulation, Blasticon Biotechnologische Forschung GmbH has made a breakthrough in cell biology:

Blasticon has at its disposal a patented technology based on which monocytes (mature white blood cells) from blood extracted from veins can be turned into cells with programmable properties comparable to those of stem cells and differentiated into different functional cells for diverse applications in diagnostics and therapy.

Cellular quick-change artists in the fight against widespread diseases

"We work with mononuclear cells, which can simply be extracted from blood," says Prof. Dr. med. Fred Fandrich, Director of the Clinic for General Surgery and Thoracic Surgery at the University Clinic of Schleswig-Holstein, Kiel, and founder of the company. "In the second step of our patented procedure we can 'reprogram' these programmable cells into the desired target cells, for example liver or muscle cells or cells in pancreatic islets of Langerhans." The therapeutic possibilities lie in replacing defective or missing cells (regenerative medicine) or producing cells that regulate the immune system. A significant advancement in the treatment of autoimmune diseases or for transplant medicine.

The "reprogrammed" cells can be used both as diagnostic agents or for therapeutic purposes. Inflammatory bowel diseases (Morbus Crohn, Colitis ulcerosa), diabetes, rheumatism, cardiac infarction, liver diseases and kidney and liver transplants, among others, are among the main therapeutic areas. Blasticon's therapeutic agents are for the most part in advanced stages of preclinical or clinical phases of development. In most cases, the medical fields of application described necessitate costly lifelong treatment. Blasticon's reprogrammed cells make it possible to attack illnesses at their origin and to prevent long duration of treatment. A further possible positive effect of the technologies is significant cost-reduction in the health system.

Products which are ready for application and soon to be introduced onto the market

The diagnostic application of the in vitro acute toxicity test "NeoHeps" can be introduced onto the market as soon as NeoHelps has been successfully validated by the European Union (EU). The REACH programme, a new EU chemical regulation that came into force on 1 June 2007 is of particular importance here; it will in future oblige all manufacturers, importers and users of chemicals to evaluate their substances as being safe. This presents a great challenge to many industries, whether they produce shampoos, kitchen utensils, computers, televisions, furniture or clothing - owing to the implementation of REACH, over 30,000 known chemicals are to be retested for their toxic safety. New chemical entities must also be tested with the REACH test regime. According to estimates, around 3,500 tests a year will be necessary.

Up to now, Blasticon's "NeoHeps" test system has passed all necessary tests within the EU test framework and has therefore been able to secure itself a clear market lead. In addition, "NeoHeps" could be of considerable benefit to the pharmaceutical industry, for example in examining the effectiveness and undesirable side effects of medicines. The advantages are less animal testing, unlimited availability of the required cells and cost-reduction in the area of drug development.

Prof. Dr. med Fandrich comments on the current political debate: "Personally, I do not think much of the use of embryonic cells for clinical application. Pure research and clinical research should be kept separate from one another. Embryonic stem cells are necessary so that we can gain a better understanding of the programmability of cells."

About Blasticon Biotechnologische Forschung GmbH

Blasticon is a biotechnology company that is active in the fields of cellular medicine and in vitro diagnostics. Blasticon has at its disposal a patented technology that enables it to turn monocytes (mature white blood cells) from extracted blood into PCMO (programmable cells of monocytic origin = stem-cell-like human cells) and to differentiate them into different functional cells for diverse applications in diagnostics and therapy. The company was founded in 2002.


PRint Agentur fur Offentlichkeitsarbeit GmbH

Katja Schmidt

Ottobrunner Strasse 26

82008 Unterhaching


Telephone: +49-89-66532-1280

Telefax: +49-89-66532-1115


SOURCE Blasticon Biotechnologische Forschung GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Germany Hosts World Leading Medical Industry Fair
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
4. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
5. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
8. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
11. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... ... 2015 , ... International Society for Pharmaceutical Engineering (ISPE) closed ... events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in Philadelphia, ... number of attendees in more than a decade. , “The 2015 Annual ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
Breaking Biology News(10 mins):